Cancer Research Versailles No Abst Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yegnasubramanian, S.
Right arrow Articles by Nelson, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yegnasubramanian, S.
Right arrow Articles by Nelson, W. G.
[Cancer Research 64, 1975-1986, March 15, 2004]
© 2004 American Association for Cancer Research

Regular Articles

Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer

Srinivasan Yegnasubramanian1, Jeanne Kowalski1, Mark L. Gonzalgo2, Marianna Zahurak1, Steven Piantadosi1, Patrick C. Walsh2, G. Steven Bova3, Angelo M. De Marzo1,2,3, William B. Isaacs1,2 and William G. Nelson1,2,3

1 Sidney Kimmel Comprehensive Cancer Center, 2 Brady Urological Institute, and 3 Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Aberrant DNA methylation patterns may be the earliest somatic genome changes in prostate cancer. Using real-time methylation-specific PCR, we assessed the extent of hypermethylation at 16 CpG islands in DNA from seven prostate cancer cell lines (LNCaP, PC-3, DU-145, LAPC-4, CWR22Rv1, VCaP, and C42B), normal prostate epithelial cells, normal prostate stromal cells, 73 primary prostate cancers, 91 metastatic prostate cancers, and 25 noncancerous prostate tissues. We found that CpG islands at GSTP1, APC, RASSF1a, PTGS2, and MDR1 were hypermethylated in >85% of prostate cancers and cancer cell lines but not in normal prostate cells and tissues; CpG islands at EDNRB, ESR1, CDKN2a, and hMLH1 exhibited low to moderate rates of hypermethylation in prostate cancer tissues and cancer cell lines but were entirely unmethylated in normal tissues; and CpG islands at DAPK1, TIMP3, MGMT, CDKN2b, p14/ARF, and CDH1 were not abnormally hypermethylated in prostate cancers. Receiver operator characteristic curve analyses suggested that CpG island hypermethylation changes at GSTP1, APC, RASSF1a, PTGS2, and MDR1 in various combinations can distinguish primary prostate cancer from benign prostate tissues with sensitivities of 97.3–100% and specificities of 92–100%. Hypermethylation of the CpG island at EDNRB was correlated with the grade and stage of the primary prostate cancers. PTGS2 CpG island hypermethylation portended an increased risk of recurrence. Furthermore, CpG island hypermethylation patterns in prostate cancer metastases were very similar to the primary prostate cancers and tended to show greater differences between cases than between anatomical sites of metastasis.




This article has been cited by other articles:


Home page
 JCOHome page
L. Richiardi, V. Fiano, L. Vizzini, L. De Marco, L. Delsedime, O. Akre, A. G. Tos, and F. Merletti
Promoter Methylation in APC, RUNX3, and GSTP1 and Mortality in Prostate Cancer Patients
J. Clin. Oncol., July 1, 2009; 27(19): 3161 - 3168.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. G. Febbo
Epigenetic Events Highlight the Challenge of Validating Prognostic Biomarkers During the Clinical and Biologic Evolution of Prostate Cancer
J. Clin. Oncol., July 1, 2009; 27(19): 3088 - 3090.
[Full Text] [PDF]

Home page
 In VivoHome page
N. RABIAU, M. O. THIAM, S. SATIH, L. GUY, J.-L. KEMENY, J.-P. BOITEUX, L. FONTANA, Y.-J. BIGNON, and D. BERNARD-GALLON
Methylation Analysis of BRCA1, RASSF1, GSTP1 and EPHB2 Promoters in Prostate Biopsies According to Different Degrees of Malignancy
In Vivo, May 1, 2009; 23(3): 387 - 391.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Greenhough, H. J.M. Smartt, A. E. Moore, H. R. Roberts, A. C. Williams, C. Paraskeva, and A. Kaidi
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment
Carcinogenesis, March 1, 2009; 30(3): 377 - 386.
[Abstract] [Full Text] [PDF]

Home page
 Lab MedHome page
A. Maxwell, C. R. McCudden, F. Wians, and M. S. Willis
Recent Advances in the Detection of Prostate Cancer Using Epigenetic Markers in Commonly Collected Laboratory Samples
Lab Med, March 1, 2009; 40(3): 171 - 178.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. D. Sorensen, P. J. Wild, A. Mortezavi, K. Adolf, N. Torring, S. Heeboll, B. P. Ulhoi, P. Ottosen, T. Sulser, T. Hermanns, et al.
Genetic and Epigenetic SLC18A2 Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy
Clin. Cancer Res., February 15, 2009; 15(4): 1400 - 1410.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Yegnasubramanian, M. C. Haffner, Y. Zhang, B. Gurel, T. C. Cornish, Z. Wu, R. A. Irizarry, J. Morgan, J. Hicks, T. L. DeWeese, et al.
DNA Hypomethylation Arises Later in Prostate Cancer Progression than CpG Island Hypermethylation and Contributes to Metastatic Tumor Heterogeneity
Cancer Res., November 1, 2008; 68(21): 8954 - 8967.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
N. Xiang, R. Zhao, G. Song, and W. Zhong
Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells
Carcinogenesis, November 1, 2008; 29(11): 2175 - 2181.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. X. Fu, J. R. Dobosy, J. A. Desotelle, N. Almassi, J. A. Ewald, R. Srinivasan, M. Berres, J. Svaren, R. Weindruch, and D. F. Jarrard
Aging and Cancer-Related Loss of Insulin-like Growth Factor 2 Imprinting in the Mouse and Human Prostate
Cancer Res., August 15, 2008; 68(16): 6797 - 6802.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-W. Liu, J. K. Nagpal, W. Sun, J. Lee, M. S. Kim, K. L. Ostrow, S. Zhou, C. Jeronimo, R. Henrique, W. Van Criekinge, et al.
ssDNA-Binding Protein 2 Is Frequently Hypermethylated and Suppresses Cell Growth in Human Prostate Cancer
Clin. Cancer Res., June 15, 2008; 14(12): 3754 - 3760.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
T M Murphy, A S Perry, and M Lawler
The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer
Endocr. Relat. Cancer, March 1, 2008; 15(1): 11 - 25.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
X. Wang, J. K.L. Colby, P. Yang, S. M. Fischer, R. A. Newman, and R. D. Klein
The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue
Carcinogenesis, January 1, 2008; 29(1): 120 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Henrique, F. R. Ribeiro, D. Fonseca, M. O. Hoque, A. L. Carvalho, V. L. Costa, M. Pinto, J. Oliveira, M. R. Teixeira, D. Sidransky, et al.
High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients
Clin. Cancer Res., October 15, 2007; 13(20): 6122 - 6129.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. H. Taylor, R. S. Kramer, J. W. Davis, J. Guo, D. J. Duff, D. Xu, C. W. Caldwell, and H. Shi
Ultradeep Bisulfite Sequencing Analysis of DNA Methylation Patterns in Multiple Gene Promoters by 454 Sequencing
Cancer Res., September 15, 2007; 67(18): 8511 - 8518.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kawamoto, S. T. Okino, R. F. Place, S. Urakami, H. Hirata, N. Kikuno, T. Kawakami, Y. Tanaka, D. Pookot, Z. Chen, et al.
Epigenetic Modifications of RASSF1A Gene through Chromatin Remodeling in Prostate Cancer
Clin. Cancer Res., May 1, 2007; 13(9): 2541 - 2548.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. R. Yates, I. Rehman, M. F. Abbod, M. Meuth, S. S. Cross, D. A. Linkens, F. C. Hamdy, and J. W.F. Catto
Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 2046 - 2053.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. S. Zorn, K. J. Wojno, M. T. McCabe, R. Kuefer, J. E. Gschwend, and M. L. Day
5-Aza-2'-Deoxycytidine Delays Androgen-Independent Disease and Improves Survival in the Transgenic Adenocarcinoma of the Mouse Prostate Mouse Model of Prostate Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 2136 - 2143.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. J. Bruxvoort, H. M. Charbonneau, T. A. Giambernardi, J. C. Goolsby, C.-N. Qian, C. R. Zylstra, D. R. Robinson, P. Roy-Burman, A. K. Shaw, B. D. Buckner-Berghuis, et al.
Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Cancer Res., March 15, 2007; 67(6): 2490 - 2496.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Roupret, V. Hupertan, D. R. Yates, J. W.F. Catto, I. Rehman, M. Meuth, S. Ricci, R. Lacave, G. Cancel-Tassin, A. de la Taille, et al.
Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage
Clin. Cancer Res., March 15, 2007; 13(6): 1720 - 1725.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S Fritzsche, M Kenzelmann, M J Hoffmann, M Muller, R Engers, H-J Grone, and W A Schulz
Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 839 - 849.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. S Perry, R. Foley, K. Woodson, and M. Lawler
The emerging roles of DNA methylation in the clinical management of prostate cancer.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. C. Myzak, K. Hardin, R. Wang, R. H. Dashwood, and E. Ho
Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells
Carcinogenesis, April 1, 2006; 27(4): 811 - 819.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. N. Poynter, K. A. Cooney, J. D. Bonner, K. A. White, L. P. Tomsho, G. Rennert, and S. B. Gruber
APC I1307K and the Risk of Prostate Cancer.
Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 468 - 473.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. A. Hanson, J. W. Gillespie, A. Grover, M. A. Tangrea, R. F. Chuaqui, M. R. Emmert-Buck, J. A. Tangrea, S. K. Libutti, W. M. Linehan, and K. G. Woodson
Gene promoter methylation in prostate tumor-associated stromal cells.
J Natl Cancer Inst, February 15, 2006; 98(4): 255 - 261.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. K. Vanaja, K. V. Ballman, B. W. Morlan, J. C. Cheville, R. M. Neumann, M. M. Lieber, D. J. Tindall, and C. Y.F. Young
PDLIM4 Repression by Hypermethylation as a Potential Biomarker for Prostate Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1128 - 1136.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
S. Yegnasubramanian, X. Lin, M. C. Haffner, A. M. DeMarzo, and W. G. Nelson
Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation
Nucleic Acids Res., February 9, 2006; 34(3): e19 - e19.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S.-Y. Chen, G. Wulf, X. Z. Zhou, M. A. Rubin, K. P. Lu, and S. P. Balk
Activation of {beta}-Catenin Signaling in Prostate Cancer by Peptidyl-Prolyl Isomerase Pin1-Mediated Abrogation of the Androgen Receptor-{beta}-Catenin Interaction
Mol. Cell. Biol., February 1, 2006; 26(3): 929 - 939.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Tominaga, S. Fujii, K. Mukawa, M. Fujita, K. Ichikawa, S. Tomita, Y. Imai, K. Kanke, Y. Ono, A. Terano, et al.
Prediction of Colorectal Neoplasia by Quantitative Methylation Analysis of Estrogen Receptor Gene in Nonneoplastic Epithelium from Patients with Ulcerative Colitis
Clin. Cancer Res., December 15, 2005; 11(24): 8880 - 8885.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Rosenbaum, M. O. Hoque, Y. Cohen, M. Zahurak, M. A. Eisenberger, J. I. Epstein, A. W. Partin, and D. Sidransky
Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy
Clin. Cancer Res., December 1, 2005; 11(23): 8321 - 8325.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Enokida, H. Shiina, S. Urakami, M. Igawa, T. Ogishima, L.-C. Li, M. Kawahara, M. Nakagawa, C. J. Kane, P. R. Carroll, et al.
Multigene Methylation Analysis for Detection and Staging of Prostate Cancer
Clin. Cancer Res., September 15, 2005; 11(18): 6582 - 6588.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary
Molecular pathology of prostate cancer
J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. S. Palapattu, S. Sutcliffe, P. J. Bastian, E. A. Platz, A. M. De Marzo, W. B. Isaacs, and W. G. Nelson
Prostate carcinogenesis and inflammation: emerging insights
Carcinogenesis, July 1, 2005; 26(7): 1170 - 1181.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. J. Bastian, G. S. Palapattu, X. Lin, S. Yegnasubramanian, L. A. Mangold, B. Trock, M. A. Eisenberger, A. W. Partin, and W. G. Nelson
Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy
Clin. Cancer Res., June 1, 2005; 11(11): 4037 - 4043.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. J. Bastian, J. Ellinger, A. Wellmann, N. Wernert, L. C. Heukamp, S. C. Muller, and A. von Ruecker
Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci
Clin. Cancer Res., June 1, 2005; 11(11): 4097 - 4106.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Lodygin, A. Epanchintsev, A. Menssen, J. Diebold, and H. Hermeking
Functional Epigenomics Identifies Genes Frequently Silenced in Prostate Cancer
Cancer Res., May 15, 2005; 65(10): 4218 - 4227.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. T. Agoston, P. Argani, S. Yegnasubramanian, A. M. De Marzo, M. A. Ansari-Lari, J. L. Hicks, N. E. Davidson, and W. G. Nelson
Increased Protein Stability Causes DNA Methyltransferase 1 Dysregulation in Breast Cancer
J. Biol. Chem., May 6, 2005; 280(18): 18302 - 18310.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
D M Peehl
Primary cell cultures as models of prostate cancer development
Endocr. Relat. Cancer, March 1, 2005; 12(1): 19 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
E. A. Platz, S. Rohrmann, J. D. Pearson, M. M. Corrada, D. J. Watson, A. M. De Marzo, P. K. Landis, E. J. Metter, and H. B. Carter
Nonsteroidal Anti-inflammatory Drugs and Risk of Prostate Cancer in the Baltimore Longitudinal Study of Aging
Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 390 - 396.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Y. P. Yu, S. Paranjpe, J. Nelson, S. Finkelstein, B. Ren, D. Kokkinakis, G. Michalopoulos, and J.-H. Luo
High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array
Carcinogenesis, February 1, 2005; 26(2): 471 - 479.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L.-C. Li, P. R. Carroll, and R. Dahiya
Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L. Gonzalgo, S. Yegnasubramanian, G. Yan, C. G. Rogers, T. L. Nicol, W. G. Nelson, and C. P. Pavlovich
Molecular Profiling and Classification of Sporadic Renal Cell Carcinoma by Quantitative Methylation Analysis
Clin. Cancer Res., November 1, 2004; 10(21): 7276 - 7283.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. G. Alleman, R. L. Tabios, G. V. R. Chandramouli, O. N. Aprelikova, C. Torres-Cabala, A. Mendoza, C. Rodgers, N. A. Sopko, W. M. Linehan, and J. R. Vasselli
The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2'-deoxycytidine
Clin. Cancer Res., October 15, 2004; 10(20): 7011 - 7021.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Enokida, H. Shiina, M. Igawa, T. Ogishima, T. Kawakami, W. W. Bassett, J. W. Anast, L.-C. Li, S. Urakami, M. Terashima, et al.
CpG Hypermethylation of MDR1 Gene Contributes to the Pathogenesis and Progression of Human Prostate Cancer
Cancer Res., September 1, 2004; 64(17): 5956 - 5962.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.